Interim Results of a Phase 1-2a Trial of Ad26.COV2.S Covid-19 Vaccine.

Sadoff J, Le Gars M, Shukarev G, Heerwegh D, Truyers C, de Groot AM, Stoop J, Tete S, Van Damme W, Leroux-Roels I, Berghmans PJ, Kimmel M, Van Damme P, de Hoon J, Smith W, Stephenson KE, De Rosa SC, Cohen KW, McElrath MJ, Cormier E, Scheper G, Barouch DH, Hendriks J, Struyf F, Douoguih M, Van Hoof J, Schuitemaker H

Open source

DOI: 10.1056/nejmoa2034201
Published: 2021 May 13
Container: The New England journal of medicine
Publisher: Not recorded
Open access: yes

Credibility signals

limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
supportingOpen access status: Normalized open-access status: open. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1056/nejmoa2034201,
  title = {Interim Results of a Phase 1-2a Trial of Ad26.COV2.S Covid-19 Vaccine.},
  author = {Sadoff J and Le Gars M and Shukarev G and Heerwegh D and Truyers C and de Groot AM and Stoop J and Tete S and Van Damme W and Leroux-Roels I and Berghmans PJ and Kimmel M and Van Damme P and de Hoon J and Smith W and Stephenson KE and De Rosa SC and Cohen KW and McElrath MJ and Cormier E and Scheper G and Barouch DH and Hendriks J and Struyf F and Douoguih M and Van Hoof J and Schuitemaker H},
  year = {2021},
  journal = {The New England journal of medicine},
  doi = {10.1056/nejmoa2034201},
  url = {https://doi.org/10.1056/nejmoa2034201}
}

RIS

TY  - JOUR
TI  - Interim Results of a Phase 1-2a Trial of Ad26.COV2.S Covid-19 Vaccine.
AU  - Sadoff J
AU  - Le Gars M
AU  - Shukarev G
AU  - Heerwegh D
AU  - Truyers C
AU  - de Groot AM
AU  - Stoop J
AU  - Tete S
AU  - Van Damme W
AU  - Leroux-Roels I
AU  - Berghmans PJ
AU  - Kimmel M
AU  - Van Damme P
AU  - de Hoon J
AU  - Smith W
AU  - Stephenson KE
AU  - De Rosa SC
AU  - Cohen KW
AU  - McElrath MJ
AU  - Cormier E
AU  - Scheper G
AU  - Barouch DH
AU  - Hendriks J
AU  - Struyf F
AU  - Douoguih M
AU  - Van Hoof J
AU  - Schuitemaker H
PY  - 2021
JO  - The New England journal of medicine
DO  - 10.1056/nejmoa2034201
UR  - https://doi.org/10.1056/nejmoa2034201
ER  -

APA

J, S., M, L. G., G, S., D, H., C, T., AM, D. G., J, S., S, T., W, V. D., I, L., PJ, B., M, K., P, V. D., J, D. H., W, S., KE, S., SC, D. R., KW, C., MJ, M., E, C., G, S., DH, B., J, H., F, S., M, D., J, V. H., & H, S. (2021). Interim Results of a Phase 1-2a Trial of Ad26.COV2.S Covid-19 Vaccine.. The New England journal of medicine. https://doi.org/10.1056/nejmoa2034201

Source records

pubmed · retrieved 2026-09-26T16:58:43.312Z